Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2019

01-01-2019 | Original Article

Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis

Authors: Russell Rosenblatt, Amit Mehta, David Snell, Erika Hissong, Andrea Siobhan Kierans, Sonal Kumar

Published in: Digestive Diseases and Sciences | Issue 1/2019

Login to get access

Abstract

Background

Nonalcoholic fatty pancreas disease (NAF-P) is strongly linked with nonalcoholic fatty liver disease (NAFLD), but its relationship with advanced liver disease is unknown.

Aims

This study investigated the association between NAF-P and both advanced fibrosis and nonalcoholic steatohepatitis (NASH).

Methods

This retrospective study evaluated adults with biopsy-proven NAFLD with a sonogram within 1 year of liver biopsy. NAF-P was diagnosed by comparing the echogenicity of the pancreas to the kidney and was graded by severity. The primary outcome was the effect of NAF-P on the presence of advanced fibrosis and NASH, while secondary outcomes included the association of extensive NAF-P (grade II/III). Propensity score matching for independent risk factors of advanced fibrosis (age, gender, body mass index, and diabetes) was performed.

Results

One hundred and four patients were included in the study and 91 (87.5%) had NAF-P. After propensity score matching, NAF-P was significantly associated with advanced fibrosis (OR 10.52, p < 0.001) but not NASH (p = 0.27). Extensive NAF-P was predictive of advanced fibrosis (OR 3.35, p = 0.006) and NASH (OR 5.37, p < 0.001). NAF-P had a negative predictive value (NPV) of 93% for advanced fibrosis. When matching for the NAFLD fibrosis score in addition to the variables above, both NAF-P (OR 5.36, p = 0.001) and extensive NAF-P (OR 5.38, p = 0.002) still significantly predicted advanced fibrosis.

Conclusion

NAF-P is predictive of advanced fibrosis, even when controlling for independent predictors of advanced fibrosis and the NAFLD fibrosis score. NAF-P has an excellent NPV and is a safe, inexpensive finding that can rule out advanced fibrosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of nonalcoholic fatty liver disease. Dig Dis. 2010;28:155–161.CrossRef Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of nonalcoholic fatty liver disease. Dig Dis. 2010;28:155–161.CrossRef
2.
go back to reference Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;116:1413–1419. Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;116:1413–1419.
3.
go back to reference Matteoni C, Younossi Z, Gramlich T, Bopari N, Liu Y, Mccullough A. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.CrossRef Matteoni C, Younossi Z, Gramlich T, Bopari N, Liu Y, Mccullough A. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.CrossRef
4.
go back to reference Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.CrossRef Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.CrossRef
5.
go back to reference Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. Mech Dev. 2003;120:59–64.CrossRef Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. Mech Dev. 2003;120:59–64.CrossRef
6.
go back to reference Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.CrossRef Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.CrossRef
7.
go back to reference Lee JS, Kim SH, Jun DW, et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol. 2009;15:1869–1875.CrossRef Lee JS, Kim SH, Jun DW, et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol. 2009;15:1869–1875.CrossRef
8.
go back to reference Boyd W. Text-book of pathology: An introduction to medicine. 3rd ed. Philadelphia: Lea & Febiger; 1938. Boyd W. Text-book of pathology: An introduction to medicine. 3rd ed. Philadelphia: Lea & Febiger; 1938.
10.
go back to reference Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc. 2014;3:e000297.PubMedPubMedCentral Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc. 2014;3:e000297.PubMedPubMedCentral
11.
go back to reference Lesmana C, Pakasi L, Inggriani S, Aidawati M, Lesmana L. Prevalence of nonalcoholic fatty pancreas disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol. 2015;15:174.CrossRef Lesmana C, Pakasi L, Inggriani S, Aidawati M, Lesmana L. Prevalence of nonalcoholic fatty pancreas disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol. 2015;15:174.CrossRef
12.
go back to reference Della Corte C, Mosca A, Majo F, et al. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf). 2015;83:656–662.CrossRef Della Corte C, Mosca A, Majo F, et al. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf). 2015;83:656–662.CrossRef
13.
go back to reference Uygun A, Kadayifci A, Demirci H, et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med. 2015;26:37–41.CrossRef Uygun A, Kadayifci A, Demirci H, et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med. 2015;26:37–41.CrossRef
15.
go back to reference Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5:e53.CrossRef Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5:e53.CrossRef
16.
go back to reference Lingvay I, Esser V, Legendre JL, et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94:4070–4076.CrossRef Lingvay I, Esser V, Legendre JL, et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94:4070–4076.CrossRef
18.
go back to reference Heni M, Machann J, Staiger H, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010;26:200–205.CrossRef Heni M, Machann J, Staiger H, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010;26:200–205.CrossRef
19.
go back to reference Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007;9:312–318.CrossRef Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007;9:312–318.CrossRef
20.
go back to reference Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877–883.CrossRef Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877–883.CrossRef
21.
go back to reference Lupşor-Platon M, Stefǎnescu H, Muresçan D, et al. Noninvasive assessment of liver steatosis using ultrasound methods. Med Ultrason. 2014;16:236–245.PubMed Lupşor-Platon M, Stefǎnescu H, Muresçan D, et al. Noninvasive assessment of liver steatosis using ultrasound methods. Med Ultrason. 2014;16:236–245.PubMed
22.
go back to reference Zezos P, Renner EL. Liver transplantation and nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532–15538.CrossRef Zezos P, Renner EL. Liver transplantation and nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532–15538.CrossRef
23.
go back to reference Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–1501.CrossRef Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–1501.CrossRef
24.
go back to reference Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2012;56:564–570.CrossRef Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2012;56:564–570.CrossRef
25.
go back to reference Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.CrossRef Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.CrossRef
26.
go back to reference Ceccarelli S, Panera N, Mina M, et al. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in nonalcoholic fatty liver disease. Oncotarget. 2015;6:41434–41452.CrossRef Ceccarelli S, Panera N, Mina M, et al. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in nonalcoholic fatty liver disease. Oncotarget. 2015;6:41434–41452.CrossRef
27.
go back to reference Oben JA, Patel T, Mouralidarane A, et al. Maternal obesity programmes offspring development of nonalcoholic fatty pancreas disease. Biochem Biophys Res Commun. 2010;394:24–28.CrossRef Oben JA, Patel T, Mouralidarane A, et al. Maternal obesity programmes offspring development of nonalcoholic fatty pancreas disease. Biochem Biophys Res Commun. 2010;394:24–28.CrossRef
28.
go back to reference Patel NS, Peterson MR, Lin GY, et al. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract. 2013;2013:1–8.CrossRef Patel NS, Peterson MR, Lin GY, et al. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract. 2013;2013:1–8.CrossRef
29.
go back to reference Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.CrossRef Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.CrossRef
30.
go back to reference Catanzaro R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol. 2016;22:7660–7675.CrossRef Catanzaro R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol. 2016;22:7660–7675.CrossRef
31.
go back to reference Sepe PS, Ohri A, Sanaka S, et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc. 2011;73:987–993.CrossRef Sepe PS, Ohri A, Sanaka S, et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc. 2011;73:987–993.CrossRef
Metadata
Title
Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis
Authors
Russell Rosenblatt
Amit Mehta
David Snell
Erika Hissong
Andrea Siobhan Kierans
Sonal Kumar
Publication date
01-01-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5295-x

Other articles of this Issue 1/2019

Digestive Diseases and Sciences 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine